Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
People who have recently experienced a stroke may be more than twice as likely to develop dementia than individuals who have not had a stroke, a new study suggests.
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval
Gilead Sciences Inc. and its partner Galapagos NV announced results from the Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis.
Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.
An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.
AstraZeneca’s anifrolumab failed to meet the experimental drug’s main target in a late-stage clinical study treating patients with moderate to severe lupus.
Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy.
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain
Citing the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.
Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.
Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.